Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
October 02, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy to Present at Cantor Fitzgerald Global Healthcare Conference
September 25, 2018 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that...
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Mission Pharmacal for Acute Otitis Externa Indication
August 06, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced the...
Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX™ in Ménière’s Disease
July 26, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced initiation...
Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 09, 2018 16:20 ET
|
Otonomy, Inc.
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today reported financial...
Otonomy to Report First Quarter 2018 Financial Results and Provide Corporate Update
May 02, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
March 08, 2018 16:24 ET
|
Otonomy, Inc.
Type C meeting completed with FDA for OTIVIDEX™ in Ménière’s disease Consistent with prior guidance, pivotal trial for OTIVIDEX to start mid-2018 Conference call and webcast today at 4:30 p.m. EST ...
Otonomy Announces Multiple Presentations for Hearing Loss and Tinnitus Programs at Upcoming Association for Research in Otolaryngology Meeting
February 06, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced seven data...
ENT and Allergy Associates Adds Depth, Breadth, Experience and Expertise to its Otology/Neurotology Division
November 04, 2016 15:12 ET
|
Ent and Allergy
TARRYTOWN, N.Y., Nov. 4, 2016 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is extremely proud and delighted to announce that Dr. Eric Smouha, currently Director of Otology and Neurology...
ENT and Allergy Associates(R) Sends Sound Waves through Middlesex County
April 20, 2016 08:25 ET
|
Ent and Allergy
TARRYTOWN, N.Y., April 20, 2016 (GLOBE NEWSWIRE) -- Hearing loss and other diseases of the ear affect approximately 50 million Americans of all ages nationwide, including in the state of New...